Monthly Injected Schizophrenia Drug Has Modest Metabolic Effects Monthly Injected Schizophrenia Drug Has Modest Metabolic Effects
Patients show small changes in weight and metabolic parameters from long-term treatment with injectable aripiprazole lauroxil (AL), new research shows.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Overdoses with aripiprazole: signs, symptoms and outcomes in 239 exposures reported to the Danish Poison Information Center - Christensen AP, Boegevig S, Christensen MB, Petersen KM, Dalhoff KP, Petersen TS.
The aim of this study was to characterize the clinical signs and symptoms of exposures to aripiprazole overdoses. We retrospectively identified all aripiprazole exposures reported to the Danish Poisons Information Center (DPIC) from June 2007 to May 2015. ... (Source: SafetyLit)
Source: SafetyLit - September 9, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

ReCor Medical adds another $12m for trial of Paradise renal denervation device
ReCor Medical last week added a $12 million contribution from Otsuka Pharmaceutical (TYO:4578) to the $10 million it raised from the Japanese conglomerate last year for a clinical trial of its Paradise renal denervation device for treating hypertension, ReCor president & CEO Andrew Weiss told MassDevice.com this morning. In May 2016 Otsuka participated in a strategic investment of an unspecified amount; Weiss told us that that round and the $12 million debt financing added last week are earmarked for the Radiance-HTN efficacy study of the Paradise device, which is designed to use ultrasound waves rather than radi...
Source: Mass Device - August 16, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Funding Roundup Wall Street Beat Hypertension ReCor Medical Source Type: news

Injectable, extended-release bipolar drug wins FDA nod
Otsuka Pharmaceutical (TYO:4578) and Lundbeck said last week that its extended-release injectable aripiprazole suspension, Abilify Maintena, won FDA approval as a maintenance monotherapy for adults with bipolar I disorder. The once-monthly intramuscular formulation was created by Otsuka and co-developed and commercialized with Lundbeck, the companies reported. Get the full story at our sister site, Drug Delivery Business News. The post Injectable, extended-release bipolar drug wins FDA nod appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 31, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Neurological Pharmaceuticals Regulatory/Compliance Wall Street Beat Lundbeck Otsuka Pharmaceutical Source Type: news

FDA Approves Long-acting Injectable for Bipolar Disorder FDA Approves Long-acting Injectable for Bipolar Disorder
The FDA has approved extended-release injectable aripiprazole for maintenance monotherapy for bipolar disorder in adults.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 31, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

Abilify Maintena (aripiprazole) for Extended-Release Injectable Suspension Approved by the U.S. FDA for Maintenance Monotherapy Treatment of Bipolar I Disorder
Valby, Denmark and Tokyo, Japan, 28 July 2017 - H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced Abilify Maintena ® (aripiprazole) for extended-release injectable suspension was approved by the U.S. Food and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 28, 2017 Category: Drugs & Pharmacology Source Type: news

Addition of Aripiprazole Ups Major Depressive Disorder Remission
Small increased likelihood of remission at 12 weeks in patients with major depressive disorder (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - July 12, 2017 Category: Psychiatry Tags: Family Medicine, Geriatrics, Internal Medicine, Nursing, Pharmacy, Psychiatry, Journal, Source Type: news

For Treatment-Resistant Depression, Add an Antipsychotic or Switch Antidepressants? (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM For patients with depression unresponsive to antidepressants, adding the antipsychotic aripiprazole seems modestly better than switching to the antidepressant bupropion, a JAMA study … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 12, 2017 Category: Primary Care Source Type: news

Study compares switching meds vs. an additional med for patients unresponsive to an antidepressant
(The JAMA Network Journals) Among patients unresponsive to an antidepressant medication, adding the antipsychotic aripiprazole modestly increased the likelihood of remission from depression compared to switching to the antidepressant bupropion, according to a study published by JAMA. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - July 11, 2017 Category: International Medicine & Public Health Source Type: news

Antipsychotics Have Side Effects, Limited Value in Pediatric Psychosis Antipsychotics Have Side Effects, Limited Value in Pediatric Psychosis
For children and adolescents with first-episode psychosis, the second generation antipsychotics quetiapine extended release and aripiprazole have equivalent efficacy, but different side effect profiles, according to a head-to-head comparison.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 26, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

FDA Approves Longer-Acting Aripiprazole for Schizophrenia FDA Approves Longer-Acting Aripiprazole for Schizophrenia
The FDA has approved a 2-month dose of aripiprazole lauroxil extended-release injectable suspension for the treatment of schizophrenia.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 6, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

FDA Approves Two-Month Aristada for Treatment of Schizophrenia
DUBLIN--(BUSINESS WIRE)--Jun. 6, 2017-- Alkermes plc (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 6, 2017 Category: Drugs & Pharmacology Source Type: news

Otsuka, Proteus resubmit FDA application for novel drug-device combination
One year after the FDA declined to approve Proteus Digital Health and Otsuka ' s new sensor-embedded formulation of Otsuka ' s antipsychotic drug Abilify, the companies are giving it another shot, resubmitting the application with additional information. (Source: mobihealthnews)
Source: mobihealthnews - May 23, 2017 Category: Information Technology Source Type: news

MassDevice.com +5 | The top 5 medtech stories for May 23, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Philips picks up airway clearance device dev RespirTech Royal Philips said today it inked a deal to acquire airway clearance solution developer RespirTech for an undisclosed amount. St. Paul, Minn.-based RespirTech was founded ...
Source: Mass Device - May 23, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Proteus, Otsuka take another run at FDA approval for Abilify-smart pill combo
Otsuka Pharmaceutical (TYO:4578) and Proteus Digital Health said today that the FDA accepted its resubmitted new drug application for their “smart pill”. The drug-device product combines Abilify and a Proteus ingestible sensor in a single tablet. The FDA is slated to make a decision on the NDA resubmission in the 4th quarter this year. Get the full story at our sister site, Drug Delivery Business News. The post Proteus, Otsuka take another run at FDA approval for Abilify-smart pill combo appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - May 23, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Otsuka Pharmaceutical Proteus Digital Health Source Type: news